Abstract: T cell activation in response to antigen is increased by the administration of binding agents that block CTLA-4 signaling. When CTLA-4 signaling is thus blocked, the T cell response to antigen is released from inhibition. Such an enhanced response is useful for the treatment of tumors, chronic viral infections, and as an adjuvant during immunization.
Type:
Grant
Filed:
December 4, 1996
Date of Patent:
April 18, 2000
Assignee:
The Regents of the University of California, Office of Technology Transfer
Inventors:
James Patrick Allison, Dana R. Leach, Matthew F. Krummel